Detailed information on the current drug pipeline. This report provides insight into the pipeline status of infertility drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of menopausal symptoms drugs by company and by stage as well as a summary of the latest news and developments in this area.

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of dental pain drugs by company and by stage as well as a summary of the latest news and developments in this area.

A new report providing analysis of the current and future market for women’s health drugs across all major indications.

The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key br

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of caries drugs by company and by stage as well as a summary of the latest news and developments in this area.

AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe.

The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highl

Detailed information on the current drug pipeline. This report provides insight into the pipeline status of urinary incontinence drugs by company and by stage as well as a summary of the latest news and developments in this area.

Urinary incontinence and overactive bladder disorders are estimated to affect more than 10% of the female population. However, presentation, diagnosis and treatments rates are poor. In the US, the employment of Continence Nurses provides an ideal oppor

Stress urinary incontinence (SUI) is the most common type of urinary incontinence in women. Up until recently there were no globally developed or widely approved pharmacological treatments for this disorder leaving women with few treatment optionsnon-i

Interstitial cystitis (IC) is considered a rare disorder and poor understanding of the underlying causes of the disorder have made diagnosis and management difficult. Moreover, this has impacted on the development of effective drugs for this disorderth

Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patients&

Mixed Urinary Incontinence (MUI) affects over 10% of women, with women suffering from unpleasant symptoms of both urge urinary incontinence (UUI) and stress urinary incontinence (SUI). At present, no pharmacological agent is able to effectively treat t

Dry Overactive Bladder (dry OAB) is considered part of the overactive bladder syndrome. However, unlike wet overactive bladder (or urge urinary incontinence), it is normally only associated with urinary urgency and frequency, and not incontinence. Even

Although there are many marketed treatments for overactive bladder, there are few available for stress urinary incontinence or interstitial cystitis. Furthermore, despite available treatments for overactive bladder, many are associated with side effect

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Identify the latest dealmaking trends in your field

Palatin Technologies’ bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).